Non‑segmental vitiligo is a skin condition in which the immune system gradually removes pigment from large areas of the skin, often affecting the face and visible parts of the body. The study is testing a new medication called GIA632, which is given as a small injection under the skin, and comparing it with a harmless substance known as placebo to see if it can help restore color to the affected areas.
The main goal of the trial is to find the dose of GIA632 that works best for increasing skin color in people with this type of vitiligo. Participants will receive a series of injections over several months, with regular check‑ins to monitor any changes in the appearance of the skin and to watch for possible side effects. The study also uses a simple scoring system called the facial Vitiligo Area Scoring Index to measure how much the facial skin has repigmented, helping researchers understand whether the treatment is effective and safe.
France 
Germany 
Italy 
Spain 
The Netherlands 
